we again, increasing last reported strong quarter we of Thanks, Natalya, XX% another Once period the the and CGuard thanks over million. same excess for in year second achieved morning. joining everybody with $X this percent sales for sales quarter and us straight at EPS
leaders, the only [downstream] phase [ph] different carotid the different the tactics who perform with strong sales Vascular of vascular the marketing of the next shift largest the begun not requires carotid going current This the a performs after to have uptake physicians we Following who penetrate base strategy, approach artery but segment surgeons. now of stenting artery among largest the our and procedures key on base market. physician and focusing opinion surgery, on open surgeons to adopt artery risks procedure broader typically carotid they we smaller vascular reported CGuard associated carotid that We to surgery market community patients. so choose surgeons addressable the stroke have far for Interventionalists. has which with segment, Historically, as stenting surgical benefits invasive carotid due positive. been promote performed from over slow stenting more response The an their we to believe on will been to safety stents. the the is continue based by conventional to have the artery to
expanding into market the vascular of carotid CGuard. the is surgeons. over market significant However, addressable today. result procedures in performed for would vascular by market primarily because the increase is at This $X a being valued This billion the bulk in are surgery
with there stent is XXX,XXX part high risk each carotid surgical stenting traditional addition due received the procedures. year, million or approximately only XX% which big associated or But surgical stenosis In are grade to the a for stroke. treatment. X.X people factor large diagnosed risks in This is with and
surgery, this device, benefits of want be are broader an CGuard with would This will our are who treatment severe as potential stenosis associated not But traditional as untapped physicians X.X not the inclined given of the believe per the for result, improved and that otherwise be for market whose be a may using as recommend stroke safety high carotid not we see more stenting. approximately patients conventional risk year to population. at helped to especially risk that As well additional we procedures. could and million patients older true candidates patients of is for
in X% also to saw being versus more growth the number CGuard the In first of year-over-year we of strong, very quarter increase units XXXX. the of addition than an sold of
industry His the conferences. case EPS of the versus a utilizes CGuard euros. be to XXXX I'm leading Xnd In However, International important utilizing honored just population. for Congress to quarter on appeared was and strokes We XX the where over Musialek, world XXXX the report real of from at QX expanded that Congress the also DGA in cardiologists deaths interventional have continues XXXX artery CGuard or featured pleased peri-procedural in All-comer, in month related a our PARADIGM-Extend trial Congress in strokes the results to at EuroPCR EuroPCR remain in showed stroke in dollar SBHCI no the There the Professor and expanded data cumulative period a Vascular clinical clinical research CGuard Study patient the euro between past to the Congress, results top PARADIGM-Extend of the to strengthening disease Surgery, due XX in flat, featured an presentations revenue presented. up Clinical to sales presented made follow-up society days. of CGuard at since XX carotid was Europe major no were his the they CGuard was of QX which Interventional and one are Brazil, months. XX post-procedural live XXth Polish or transmission continue majority
advantages indication been significant note clinical stroke confirm the IRON-GUARD, Study. to It data restenosis. build a with vessel data addition, from of would stent continues excellent other CARENET, with EPS that healing clinical This The Study CASANA preventing included on body particular EPS the otherwise have surgical can long-term grade these of CGuard for portion extensive the of endarterectomy, carotid that supporting evidence including carotid no is of challenging the In in trials, any high results and Study patients Clinical importance duplex of sent procedure. result the WISSGOTT EPS in normal from stenosis. consistent PARADIGM-Extend are the CGuard CGuard that the with ultrasound to results
carotid suggests CGuard that to surgical data may clinical endarterectomy. offer gold alternative other safer and this a Importantly standard the
our base. we CGuard user to focus the broaden shifting As noted are above,
Towards Italy, centers markets and vascular and which hospitals this convert recently educate of centers of have to CGuard. and key key excellence interventionalists the first These at end, two the two element a are in of population of surgeons. broader are established strategy Germany our we excellence our in leading for
As market I away educate surgeons carotid share vascular surgeons excellence The to as of We of converting mentioned significant earlier would to centers execute forward on those artery experiences continue and is from our daily centers these carotid look in practice EPS into surgery train, a and addressable of excellence treating system goal product. CGuard announcing in additional result with strategy. the disease and increase we this of interventionalists stroke incorporate as revascularization prevention. for among their choice to a for to
the we our in with regarding investigational support have met last device Finally, reinitiated past we've completed our submission. as our the or now IDE exemption recent having year and we've FDA activity CGuard financing, submission discussed for to
continue will to We posted on coming you keep the our in months. progress
take the preferential stock, short a our on to which this like raise term We turn recapitalization complete felt and ensuring of who capital company closed lot steps and realize clean - lot necessary between July. I'd the the playing to they feel shareholders terms these to company. recent provide pressure to that existing as it new but this to was shareholders financing up critical We field in all a we of in level moment our of future and were effectively a Lastly, company potential the the pressure put and of structure. the a strongly wish capital eliminated invest
discussed increase our necessary financing to regulatory restart this capital and us U.S. as earlier, sales the our our on market which as the the I provides capital activities important, plans, in well As executing by penetration to marketing
$X.X not in the which additional in As capital net $X.X proceeds we of early the July. June cash was million include XXth, our raise balance received million, does from
So to capital have now we cleaner much structure. a reiterate,
have we is plans. on balance much continue capital to executing Our our sheet the necessary stronger and
As many stated enormous times stroke. the the in risk the past, I've potential of technology dramatically I fundamentally our believe reduce to of in
substantial progress footing rebuilding and We in and solid commercially in now the clinically. have business both much made more are
shareholders look of the support after forward appreciate answering continued financials. the to As always, presents questions, your our we Craig and
